Generex Biotech Corp

Villages sealed off as bird flu reaches outskirts of capitalTony Halpin in Moscow
Thousands of Russians were undergoing tests last night after an outbreak of bird flu at chicken farms on the outskirts of Moscow.

Health officials confirmed that chickens at two farms within 30 miles (49km) of the capital had died from the H5N1 strain of the virus. Dead birds suspected of being contaminated were also being tested at three other locations near Moscow.

“Medical monitoring is under way for 5,453 residents in the relevant areas, including 20 citizens who were in direct contact with the infected birds,” said Gennady Onishchenko, Russia’s chief epidemiologist. No illnesses had been reported among human beings so far, he said.

This is the first time that bird flu has been detected so close to Moscow, which is home to more than ten million people. Officials established quarantine zones around villages in affected areas and began bird vaccination programmes. Veterinary officials have established that the bird flu virus came from chickens bought at a Moscow bird market. More than 150 birds have died at private farms around the city in the past ten days.

Background
HN51: The Facts
Junk medicine: avian flu
Weakness found in flu virus opens door to new remedies
Trade in wild birds stopped at a stroke
“From the very beginning we have been taking safety measures, assuming that it was this strain, so the confirmation does not change anything,” said Nikolai Vlasov, director of veterinary inspection for Russia’s state agricultural agency.

The virus was found previously in 2005 in poultry plants in the Krasnodar region of Russia, 625 miles south of Moscow.

Sergei Yeremin, director of the World Health Organisation’s bird flu programme in Russia, said that this experience had left the country “highly prepared” for the present outbreak.

“There have been no cases of human infection in Russia, though it is located in a migratory zone for wild birds. This is one of the signs that Russia is ready,” he said.

“What worries us more is the source of the infected birds, how they wound up at the market.”

The Moscow regional prosecutor said that it had begun a criminal inquiry to establish “the source of the illness and the guilty parties who violated veterinary rules”.

Russia’s Interior Ministry ordered measures to prevent any possible spread of the infection. Police visited every house in the affected districts to seek information about possible sick birds, while road traffic inspectors were checking all poultry vehicles.

Valery Sitnikov, Moscow’s chief veterinarian, said that he was confident that the spread of the virus had been contained. “The incubation period of the disease is one to two days, which means that if there had been a massive die-off of hens elsewhere, we would have learnt about it,” he said.

Estonia responded to the outbreak by banning the sale of birds in markets. Azerbaijan also banned imports of poultry from farms around Moscow.  

Initial tests on two dead birds found in Hong Kong indicate they had a strain of avian flu, the southern Chinese territory's authorities said Thursday.

A spokesman for the Agriculture, Fisheries and Conservation Department said the carcasses of a Chestnut Munia and Scaly-breasted Munia tested positive for the H5 virus.

The dead birds, the ninth and 10th found in Hong Kong with avian flu, were collected on February 18 and 19. The spokesman said more tests were being conducted to confirm preliminary results.

 

Jesup & Lamont Initiates Coverage of Generex Biotechnology With "Buy" Rating and Price Target of $3.25
Thursday February 22, 2:26 pm ET

NEW YORK--(MARKET WIRE)--Feb 22, 2007 -- Jesup & Lamont, a New York-based full-service brokerage and investment banking firm, announced today that it has initiated coverage of Generex Biotechnology (NasdaqCM:GNBT - News) with a "Buy" rating and 12-18 month price target of $3.25 per share.
Senior Healthcare Analyst Robert M. Wasserman noted that, "Generex has a deep pipeline, an active industry education program (particularly in the worldwide diabetes market), growing product sales, and plenty of financial resources to provide investors with value-producing progress in the near future."  

Jesup & Lamont Initiates Coverage of Generex Biotechnology With "Buy" Rating and Price Target of $3.25
Thursday February 22, 2:26 pm ET

NEW YORK--(MARKET WIRE)--Feb 22, 2007 -- Jesup & Lamont, a New York-based full-service brokerage and investment banking firm, announced today that it has initiated coverage of Generex Biotechnology (NasdaqCM:GNBT - News) with a "Buy" rating and 12-18 month price target of $3.25 per share.
Senior Healthcare Analyst Robert M. Wasserman noted that, "Generex has a deep pipeline, an active industry education program (particularly in the worldwide diabetes market), growing product sales, and plenty of financial resources to provide investors with value-producing progress in the near future."  

Habe euch ja vor einigen Tagen bereits gesagt Generex zu kaufen, trotz der kleinen Steigerung heute ist Generex erst am Anfang seiner Entfaltung, falls bei denen eine grosse Biotech-Firma einsteigt, und alles andere würde mich wundern (die Patente und
das Know-How im den Bereichen Impfstoffe, Diabetes, usw. sind extrem anziehend), dann
sind zweistellige US-Dollar Aktienpreise möglich...abgesehen von einer möglichen H5N1 Virus-Epidemie (Generex besitzt eine Technologie zum Herstellen von synthetischen Impstoffen welche die einzige Möglichkeit bittet grössere Menschenmengen innerhalb kürzester Zeit zu impfen).
Also sagt nicht später ihr hättet es nicht gewusst!
Good Trading
Murenabob  

Europe warned on flu pandemic planning
By Andrew Jack in London

Published: February 22 2007 10:47 | Last updated: February 22 2007 10:47

Europe needs at least two more years to be prepared adequately for a pandemic flu outbreak in humans, according to the head of the European Union agency in charge of tackling infectious disease.

In an interview with the FT, Zsuzsanna Jakab, director of the European Centre for Disease Prevention and Control, said it would take two to three years to be “much better prepared to respond”, even if the current political momentum could be maintained.

Speaking ahead of the launch of a report by her agency analysing pandemic planning across the EU, she warned that countries still needed to do much more to prepare for pressures beyond their health systems and to step up sharply co-operation with each other.

She said countries needed to get their written national plans operational so they worked at the local level; and ensure plans between and within countries worked in a co-ordinated fashion.

“There are certain issues that cannot be solved by one country, and they have to work together across borders,” she said, stressing she wanted to strengthen collaboration with the EU’s close neighbours – including with Turkey, Ukraine, Belarus, Moldova and Russia – in an effort to prepare for a pandemic.

Ms Jakab said the UK, France and Germany, as well as Slovenia and the Nordic countries, were better prepared, while EU accession states in central and eastern Europe presented “a bigger challenge”.

However, she said no European country had yet published a pandemic plan across all government dep-artments, with most still focused on the health system, while only 14 had undertaken joint work with neighbouring countries.

She warned that while EU and national leaders had helped to provide significant support in recent months, there was a challenge to maintain efforts at a time when avian flu in Europe had been less significant.

Just a few outbreaks of H5N1 in birds – notably in the UK and Hungary – have taken place in recent months within the EU, although the infection continues to be endemic in animals in parts of Asia and has killed 167 people and infected 274 worldwide.

A survey of 25 EU states plus Iceland and Norway to be released on Thursday analysing pandemic planning up until last October highlighted that just 13 had contingency plans for non-essential health services, and only 15 had conducted an exercise to test plans nationally in the health sector.

Ms Jakab called for in-creased efforts to tackle seasonal influenza, including greater use of flu vaccines, which would help prepare for a pandemic.

Just 18 countries currently have a national pandemic vaccination strategy developed.  

KUWAIT CITY (AFP) - Kuwait announced on Sunday that it had detected the deadly strain of avian influenza in poultry and birds such as falcons and had shut the nation's only zoo.

"Twenty cases of avian influenza have been detected in birds, most of them falcons," Sheikh Ahmed Abdallah Al-Sabah said in a statement.

Ministry spokesman Ahmad al-Shatti told AFP it was the deadly H5N1 form of the disease, which according to the World Health Organisation has killed 167 people worldwide since it emerged in 2003.

A nationwide emergency response programme has been enacted, including the banning of all bird imports and the temporary closure of Kuwait Zoo and bird market.

The last case of avian flu in Kuwait was discovered in November 2005.

The statement said the cases, mostly in falcons, were confirmed by local and British laboratories and that more tests were being conducted.

Shatti said the ministry has taken blood samples from all people suspected of having contact with the infected birds and were being tested.

He said about 30 teams have been deployed to various parts of the oil-rich Gulf states following the discovery of the virus.

Some of the infected birds were found in Wafra farms area on the border with Saudi Arabia, while others were found at the only zoo in the country.

Kuwait is a member of the six-nation Gulf Cooperation Council which has drawn up a common strategy to combat the virus amid warnings by officials that the region was vulnerable because of migratory birds.

Individually, GCC states have recently adopted measures to prevent the spread of avian flu, including the ban of birds, poultry and their products mainly from countries in Asia and Europe where bird flu cases have surfaced.

Some countries, including Saudi Arabia, have also earmarked millions of dollars to buy drugs to combat the disease.  

Generex Biotechnology Announces Middle Eastern Licensing Agreement for Generex Oral-lyn(TM)Monday April 23, 9:45 am ET

Leading Middle Eastern Distributor of Healthcare Products to Offer Generex Oral-lyn in 15 Countries

WORCESTER, MA--(MARKET WIRE)--Apr 23, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into an exclusive Master Product Licensing & Distribution Agreement with Leosons General Trading Company, a leading distributor of North American products in the Middle East, for the commercialization of Generex Oral-lyn, the Company's proprietary oral insulin spray product, in 15 Middle Eastern countries, including Saudi Arabia and the United Arab Emirates (UAE). In lieu of Generex receiving an upfront license fee, Leosons will bear any and all costs associated with the procurement of governmental approvals for the sale of the product, including any clinical and regulatory costs. The Agreement obligates Leosons to file all requisite applications for the approvals by the fall of 2007.
ADVERTISEMENT


According to the International Diabetes Federation, the UAE has the second highest rate of diabetes in the world, affecting 70% of residents. Other Gulf states also have significant diabetes problems, with Saudi Arabia ranked third, Bahrain fourth, Kuwait fifth, and Oman sixth. Leosons General Trading Company, based in the United Arab Emirates, will procure all Middle Eastern governmental approvals for the importation and sale of Generex Oral-lyn. Thereafter, Leosons will market and sell the product through its extensive distribution network in the region. Leosons will, at its sole expense, design and implement plans for the education and training of patients and physicians in respect of the Company's RapidMist(TM) Diabetes Management System and the marketing, distribution, and sale of Generex Oral-lyn in the region. Leosons will also be obligated to achieve minimum quarterly sales of the product.

"We are delighted to have licensed Generex Oral-lyn to Leosons, a company with extensive Middle Eastern product distribution experience, to advance the commercialization of Generex Oral-lyn in the region," said Anna Gluskin, the Generex President & Chief Executive Officer. "Diabetes represents a major unmet medical need in the region and by securing distribution through a major distributor we believe we will be able to capitalize on this significant opportunity."

About Leosons
Leosons is a 25-year old private multinational operating company in the Middle East focusing on the pharmaceutical and healthcare industry. Leosons distributes 15 healthcare-related products which are considered category leaders.  

Generex Biotechnology Announces Treatment of First Breast Cancer Patients in Phase II Clinical Trial, Wednesday May 2, 8:00 am ET

Trial of Second Generation Immunotherapeutic Vaccine Being Conducted With U.S. Military Cancer Institute's Clinical Trials Group

WORCESTER, MA--(MARKET WIRE)--May 2, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that the first patients have been treated in a Phase II clinical trial of its novel immunotherapeutic vaccine AE37 being developed by Generex's wholly owned Antigen Express subsidiary. The trial is being conducted with the United States Military Cancer Institute's (USMCI) Clinical Trials Group pursuant to a Clinical Trial Agreement under the direction of COL George Peoples, M.D. The endpoint for this study is the rate of relapse in patients with node-positive or high-risk node-negative breast cancer after two years.

The study is randomized and will compare patients treated with AE37 plus the adjuvant GM-CSF versus GM-CSF alone. The goal is to demonstrate at least a 50% reduction in the rate of relapse in patients treated with AE37. The Phase II trial follows a Phase I trial (begun in April 2005) that demonstrated safety, tolerability, and immune stimulation of the AE37 vaccine in breast cancer patients.

The immunotherapeutic vaccine being developed by Antigen Express represents a second generation peptide vaccine for cancer immunotherapy. AE37 was designed using a fragment of the HER-2/neu oncoprotein modified by proprietary means to enhance its ability to activate T helper cells for recognition of HER-2/neu. The advantages of this type of active immunotherapy are both safety and the ability to have activated immune cells patrolling for cancer cells long after the therapeutic has been given.

In addition to the current Phase II breast cancer trial, AE37 is also being investigated in a Phase I trial in patients with HER-2/neu-expressing prostate cancer. Antigen Express has also developed a prophylactic vaccine for the potentially pandemic H5N1 avian influenza virus that is currently in Phase I clinical trials; that vaccine was designed using the same technology platform as that used for AE37.

"We are excited to be entering this new phase of clinical testing for efficacy after a Phase I trial that demonstrated strong immunotherapeutic results," said Anna Gluskin, President & Chief Executive Officer of Generex Biotechnology. "Given the limitations of traditional chemotherapy, active immunotherapy represents a promising new modality for the treatment of cancer."  

der aktuelle Kursverlauf scheint mir eine absichtliche Kursmanipulation von Profis zu sein...GENEREX ist gerade zum aktuellen Preis ein Longplay mit extremen Gewinnchancen.  

hat´s gemerkt!!!
Ist das der Grund für die Kursexplosion seit dem 12.06.2007?
Generex Biotechnology Corp. (GNBT US) rose 59 cents, or 47 percent, to $1.85.
The Canadian biotechnology company said its loss in the third quarter narrowed
to 7 cents a share from 36 cents a year earlier.

 

Rodman and Renshaw Initiates Coverage of Generex Biotechnology With Market Outperform Rating and $6.00 Price Target

Tuesday, June 12, 2007



WORCESTER, MA--(MARKET WIRE)--Jun 12, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Rodman & Renshaw, a New York-based investment bank, initiated coverage of the Company with a "Market Outperform" rating and an 18-month price target of $6.00. The report was issued by Navdeep S. Jaikaria, Ph.D., a Managing Director in the Equity Research Division.

The reported noted that, "Our analysis indicates that Generex's oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn's product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013. Generex also has two other smaller products in diabetes and an early-stage cancer vaccine pipeline."

The report also stated that, "We believe that Generex's Oral-lyn has advantages over other non-injectable insulin solutions. While many of these systems deliver insulin to the lungs and bronchial tree, Oral-lyn delivers insulin to the oral mucosa, avoiding the potential risks of chronic lung tissue exposure to insulin. Additionally, pharmacokinetic studies have shown that Oral-lyn reaches peak circulating levels in 30 minutes compared to 60 minutes with injected insulin. This more rapid onset will offer patients a better quality of life by providing more flexibility at meal times, and better glycemic control."

About Rodman & Renshaw:

Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. Rodman employs dedicated, experienced, and talented professionals within its equity research, corporate finance, and sales & trading divisions.  

Bin bereits seit mindestens 2 Jahren überzeugt von Generex...habe auch noch mal bei ca.1,30 US-Dollar kräftig zugelangt und bei über 2 Dollar gestern verkauft...kurzfristig bin ich also raus da GNBT momentan wahrscheinlich etwas konsolidieren wird...sobald jedoch der Preis wieder stabil ist ..wird wieder zugelangt.
Rechne dass GNBT bis min.1,70 US-Dollar abschmieren wird...hoffe dass sie noch tiefer gehen wird...auf 24 Monate rechne ich jedoch mit 6-10 Dollar.  

. . . nichts los und nichts in Sicht.
Immer wieder Abzocke in USA: Hochpushen, run auslösen und abkassiern.
Ich bin enttäuscht und entsetzt.
Gibt es noch andere Meinungen hier??  

Es war schon ein wenig merkwürdig, dass die Aktie stetig gefallen ist.

Vermutlich war da jemand am drücken.

Nun geht die Post wohl scheinbar ab - 450% in 2 Tagen!

Nachdem gestern die guten Ergebnisse der Phase III Studie bekanntgegeben wurden und sich die Verkaufszahlen in Indien verdoppelt haben.

Wer bei 8ct eingestiegen ist, der kann sich jetzt glücklich schätzen!

 

 

nun steht sie sogar schon über 0,6€
weiß einer genauer, was da gerade läuft?

der Anschiss. Erst steigt der Share auf über einen Dollar und danach wird abgeladen. Volumen über 70 Mio Shares.  

http://www1.generex.com/fckuploads/file/...1%20Vitamin%20Retailer.pdf

http://investor.generex.com/releasedetail.cfm?ReleaseID=387995  

 

Generex Presented Positive Study Data At the American Diabetes Association Scientific Sessions

   * On Tuesday June 9, 2009, 8:30 am EDT
http://finance.yahoo.com/news/...-Presented-Positive-pz-15475138.html

Gehts drüber ??

Bin gespannt.

Großes Volumen heute und wenn sich der Markt einigermaßen hält denke ich haben wir ne reelle Chance den Dollar zu packen.  

 

Generex Biotechnology Granted Five New Patents in Various Countries for Drug Delivery Systems - Quick Facts



(RTTNews) - Friday, Generex Biotechnology Corp.(GNBT), drug delivery systems and technologies provider, said it received five new patents in Canada, Australia, New Zealand, Brazil and Lebanon.

Generex added that the patents provide additional protection for its proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications.

With the addition of these patents, Generex noted that it now holds an aggregate of 146 patents worldwide, including 21 in the United States, and has an aggregate of 116 patent applications pending in various jurisdictions throughout the world.

For comments and feedback: contact editorial@rttnews.com  

Was sagt dir/euch das ganze?!

WORCESTER, Mass., June 12, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News; www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it intends to complete a registered direct offering of up to 17,200,000 shares of its common stock to accredited investors on Monday, June 15, 2009. The per share price will be $0.6389. In addition, the Company will provide 50% warrant coverage, exercisable beginning 183 days following the closing date for a period ending on the fifth anniversary of the initial exercise date, with an exercise price of $0.76 per share.

Kommplette Link:
http://finance.yahoo.com/news/...-Biotechnology-pz-15515692.html?.v=1